Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 801

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 7A
Chunk 801
---
We
are a smaller reporting company as defined by Item 10 of Regulation S-K and are not required to provide the information otherwise required
under this Item 7A.

Item
8. Financial Statements and Supplementary Data.

The
information required by this item is presented at the end of this Annual Report beginning on page F-1 and is incorporated herein by reference.
An index of those financial statements is found in Part IV, Item 15, Exhibit and Financial Statement Schedules, of this Annual Report.

Item
9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.

None

 61 

Item
9A. Controls and Procedures.

Evaluation
of Disclosure Controls and Procedures

The
Company has adopted and maintains disclosure controls and procedures that are designed to provide reasonable assurance that information
required to be disclosed in the reports filed under the Exchange Act, such as this Annual Report, is collected, recorded, processed,
summarized, and reported within the time periods specified under the rules of the SEC. As of December 31, 2024, the end of the period
covered by this Annual Report, our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of our “disclosure
controls and procedures,” as defined in Rule 13a-15(e) under the Exchange Act\. The Chief Executive Officer and Chief Financial
Officer assessed the effectiveness of our disclosure controls and procedures as of December 31, 2024. Based on their assessment, they
have concluded that, as of December 31, 2024, our disclosure controls and procedures are effective.

Internal
Control over Financial Reporting

Management’s
Annual Report on Internal Control over Financial Reporting

Our
management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined
in Rule 13a-15(f) of the Exchange Act. Our internal control system is designed to provide reasonable assurance regarding the preparation
and fair presentation of financial statements for external purposes in accordance with GAAP. All internal control systems, no matter
how well designed, have inherent limitations and can provide only reasonable assurance that the objectives of the internal control system
are met.

Our
management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures
and our internal control processes will prevent all errors or fraud. A control system, no matter how well conceived and operated, can
provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further